Clinical studies
Prospective Phase II Trial of Prognostication by 68Ga-NOTA- AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Ulrich Knigge, and Andreas Kjaer
Journal of Nuclear Medicine September 2022; 63:1371–1377
DOI: 10.2967/jnumed.121.263177
Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study
Louise M. Risør, Malene M. Clausen, Zaza Ujmajuridze, Mohammed Farhadi, Kim F. Andersen, Annika Loft, Jeppe Friborg, and Andreas Kjaer
Journal of Nuclear Medicine August 2022; 63:1169–1176
DOI: 10.2967/jnumed.121.262866
Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
Marie Øbro Fosbøl, Sorel Kurbegovic, Helle Hjorth Johannesen, Martin Andreas Røder, Adam Espe Hansen, Jann Mortensen, Annika Loft, Peter Meidahl Petersen, Jacob Madsen, Klaus Brasso and Andreas Kjaer
Journal of Nuclear Medicine March 2021, 62 (3) 354-359
Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET b Imaging
Skovgaard D, Persson M, Brandt-Larsen M, Christensen C, Madsen J, Klausen TL, Holm S, Andersen FL, Loft A, Berthelsen AK, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.
J Nucl Med 2017; 58: 379-386
PMID: 27609788
First-in-human uPAR PET: Imaging of Cancer Aggressiveness
Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A, Berthelsen AK, Ploug M, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.
Theranostics 2015; 5: 1303-16
PMID: 26516369
Preclinical studies
Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR)
Loft MD, Sun Y, Liu C, Christensen C, Huang D, Kjaer A, Cheng Z.
Amino Acids 2017; 49: 1089-1100
PMID: 28316028
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma
Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.
J Nucl Med 2016; 57: 272-8
PMID: 26429955
Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging
Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P, Kjaer A.
Nucl Med Biol 2014; 41: 290-5
PMID: 24533988
Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies
Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.
Theranostics 2013; 3: 618-32
PMID: 24052804
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts
Persson M, Liu H, Madsen J, Cheng Z, Kjaer A.
Nucl Med Biol 2013; 40: 618-24
PMID: 23602763
Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion
Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A.
J Nucl Med 2012; 53: 138-45
PMID: 22213823
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers
Persson M, Madsen J, Østergaard S, Ploug M, Kjaer A.
Nucl Med Biol 2012; 39: 560-9
PMID: 22172391